Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1971 Mar;41(3):454-61.
doi: 10.1111/j.1476-5381.1971.tb08043.x.

Central autonomic effects of prostaglandin F2 alpha on the cardiovascular system of the dog

Central autonomic effects of prostaglandin F2 alpha on the cardiovascular system of the dog

H A Lavery et al. Br J Pharmacol. 1971 Mar.

Abstract

1. Prostaglandin F(2alpha) infused into the vertebral artery of the anaesthetized greyhound in doses which had no effect when given intravenously ((8-64 ng/kg)/min) caused an increase in blood pressure and heart rate.2. This response was not significantly altered by beta-adrenoceptor blockade with propranolol (10 mg i.v.) or by cervical cord section at C(4-6).3. The tachycardia was abolished and the pressor response greatly reduced by vagotomy or atropine (250 mug/kg i.v.).4. The pressor response which remained after vagotomy was abolished by subsequent sympathetic blockade with bethanidine (2-3 mg/kg i.v.) or bretylium (10 mg/kg i.v.).5. In contrast to the effects of propranolol or cervical cord section bethanidine (4-5 mg/kg i.v.) or bretylium (10 mg/kg i.v.) significantly reduced blood pressure and heart rate responses to intravertebral prostaglandin F(2alpha). This result suggests that bethanidine and bretylium have some central actions.6. It is concluded that the cardiovascular effects of intravertebral infusions of prostaglandin F(2alpha) are mediated by the autonomic nervous system and that the preferential pathway is withdrawal of vagal tone to the heart.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Pharmacol Chemother. 1966 May;27(1):157-63 - PubMed
    1. J Physiol. 1967 Jul;191(2):134P-135P - PubMed
    1. J Physiol. 1968 Apr;195(3):731-41 - PubMed
    1. Physiol Rev. 1969 Jan;49(1):122-61 - PubMed
    1. Int J Neuropharmacol. 1969 Jan;8(1):15-24 - PubMed

LinkOut - more resources